Background: This study was conducted to evaluate the effects of probiotic supplementation
| INTRODUCTION
Diabetic foot ulcer (DFU) is one of the most serious complications of diabetes mellitus (DM) and a main risk factor for plantar ulceration. 1 Up to 25% of patients with diabetes are at risk of developing DFU during their lifetime, and poor wound healing is an initial reason for morbidity and mortality among those patients. 2 Ischaemia, neuropathy, and infection are 3 pathological elements that result in DFU complications. 3 Furthermore, hyperglycaemia, hyperinsulinemia, dyslipidemia, increased biomarkers of inflammation, and oxidative stress play the main functions in the pathogenesis of DFU. 4, 5 Diabetic foot infections and delayed wound healing are suggested as the major therapeutic difficulties associated with DFU. 6 Because of the increasing global antimicrobial drug resistance issues, the idea of probiotic consumption is interesting and pertinent, because probiotics have the ability to strengthen the immune system, have anti-inflammatory effects, and therefore, could increase the wound healing process. 7 Hence, a novel approach like probiotics intake can eliminate pathogenic microbes and possibly improve the healing process.
Probiotics might have a positive impact on metabolic control. We have previously demonstrated that multispecies probiotic administration after 8 weeks among patients with diabetes prevented a rise in the fasting plasma glucose (FPG), and led to a decrease in serum high-sensitivity C-reactive protein (hs-CRP) and an increase in plasma glutathione (GSH) levels, but did not affect indices of insulin metabolism and lipid profiles. 8 It has also been reported that probiotic supplementation for 6 weeks among subjects with type 2 DM significantly decreased FPG, haemoglobin A1c (HbA1c), and total-cholesterol and LDL-cholesterol concentrations, as well as increased erythrocyte superoxide dismutase, GSH peroxidase activity, and total antioxidant status. 9, 10 Improvement of insulin metabolism, lipid profiles, biomarkers of inflammation, and oxidative stress by probiotics might be due to their effects on scavenging superoxide and hydroxyl radicals, 11 reduced production of inflammatory cytokines, 12 and decreased adiposity. 13 As there is evidence that probiotic intake may accelerate wound healing and has anti-diabetic effect, we hypothesized that probiotic supplementation might help subjects with DFU to heal their wound faster, and have a better metabolic profiles, and biomarkers of inflammation and oxidative stress. The aim of the current study, therefore, was to determine the effects of probiotic supplementation on wound healing and metabolic status in subjects with DFU. Also, 90% of patients in both groups were prescribed metformin with no antiplatelet, anticoagulants, or any other glucose lowering drugs, such as dipeptidyl peptidase 4. Randomization assignment was conducted by using computer-generated random numbers. Randomization and allocation were concealed from the researchers and participants until the final analyses were completed. The randomized allocation sequence, enrolling participants, and allocating them to interventions were conducted by a trained staff at the clinic. Participants were requested not to change their usual physical activity and not to take any nutritional supplements during the 12-week treatment. All subjects completed 3-day food records and 3 physical activity records at baseline, weeks 3, 6, and 9 of the intervention and end-of-trial. Daily macronutrient and micronutrient intakes were analysed by nutritionist IV software (First Databank, San Bruno, CA). Physical activity was described as metabolic equivalents (METs) in hours per day. To determine the METs for each patient, we multiplied the times (in hour per day) reported for each physical activity by its related METs coefficient by standard tables. 20 
| Assessment of anthropometric measures
Weight and height of participants were determined in an overnight fasting status by using a standard scale (Seca, Hamburg, Germany) at the onset of the study and 12 weeks after treatment. Body mass index was calculated as weight in kilograms divided by height in meters squared.
| Assessment of outcomes
Wound healing and glucose homeostasis parameters were considered as the primary outcome variables and lipid profiles, and biomarkers of inflammation and oxidative stress were considered as the secondary outcomes variables.
| Clinical assessment
Mean ulcer area was estimated as the product of longest measured length times longest perpendicular to length. Ulcer volume was estimated as the estimated area times the deepest ulcer depth. 21 Depth ulcer was measured by using a sterile blunt nasal probe. 21 Infection was diagnosed if oedema, erythema, discharge, regional lymph node enlargement, pain, or fever was present. 22 Participants were considered positive for infection if at least 2 of the above listed features were present. Each foot was evaluated and graded according to the Wagner classification.
| Biochemical assessment
At baseline and after the 12-week intervention, 10 mL fasting blood samples were obtained from each patient at Babol reference laboratory. Then, the samples were stored at −80°C before analysis. Serum were assessed by using Griess method. 24 Plasma total antioxidant capacity (TAC) concentrations by the method of ferric reducing antioxidant power developed by Benzie and Strain, 25 GSH using the method of Beutler et al, 26 and malondialdehyde (MDA) concentrations by the thiobarbituric acid reactive substances spectrophotometric test 27 were evaluated. All interassay and intraassay CVs for NO, TAC, GSH, and MDA concentrations were less than 5%.
| Sample size
To calculate the sample size, we used a formula suggested for clinical
Given the type I error of 5% (α = 0.05) and type II error of 20% (β = 0.20; power = 80%) and 1.61
as the SD of HOMA-IR based on a previous study 8 and the d (the difference between the 2 groups that has been considered as significant) value of 1.30, we reached the sample size of 25 individuals for each study group. Assuming 5 dropouts in each group, the final sample size was determined to be 30 persons in each group.
| Statistical analysis
To ensure the normal distribution of variables, the Kolmogorov- (Table 1) .
Based on the 3-day dietary records obtained at baseline, end-oftreatment, and throughout the trial, we found no significant difference in mean dietary macronutrient and micronutrient intakes between the 2 groups (data not shown).
After the 12-week intervention, compared with the placebo, probiotic supplementation led to significant reductions in ulcer length (−1.3 ± 0.9 vs. −0.8 ± 0.7 cm, P = .01), width (−1.1 ± 0.7 vs.
−0.7 ± 0.7 cm, P = .02), and depth (−0.5 ± 0.3 vs. −0.3 ± 0.3 cm, P = .02) (Table 2) . Furthermore, significant reductions in FPG (−29.6 ± 30.3 vs. There was a significant difference in the baseline levels of serum HDL-cholesterol (P = .04) between the 2 groups. Therefore, we adjusted the analysis for baseline values of biochemical parameters, age, and baseline BMI. When we adjusted the analysis for few confounding variables, including baseline values of biochemical parameters, age, and baseline BMI, HOMA-B became statistically significant (P = .01) and other findings did not change (Table 3) .
| DISCUSSION
To our knowledge, this study is the first report of probiotic supplementation on wound healing, glucose metabolism, lipid profiles, and biomarkers of inflammation and oxidative stress among subjects with DFU. We found that probiotic supplementation for 12 weeks among subjects with DFU had beneficial effects on ulcer size, glucose metabolism, total cholesterol, hs-CRP, plasma NO, TAC, and MDA levels but did not affect HOMA-B, other lipid profiles, and biomarkers of inflammation and oxidative stress. It must be considered that in the present study, observed changes in ulcer size in the probiotic group compared with placebo group were clinically significant. On the other hand, the percentage of those who was treated after intervention was significantly different between the 2 groups (60.0% for probiotic + antibiotics group vs. 31.0% for placebo + antibiotics group, P = .02).
This study demonstrated that probiotic supplementation for 12 weeks in patients with diabetes who suffer from DFU resulted in a significant improvement in parameters of wound healing compared with the placebo. However, data on the effects of probiotics on the wound healing in human studies are scarce. In an animal study by Huseini et al, 28 it was observed that Kefir products resulted in enhanced healing of burn injury on rat skin. Yogurt intake containing
Lactobacillus gasseri for 10 days at a dose of 5 mL/kg in rats significantly accelerated the healing of the ulcer. 29 Furthermore, the cells from ulcer beds collected after Lactobacillus plantarum treatment for 10 days decreased wound bacterial load, apoptotic and necrotic cells, modified interleukin 8 productions, and induced wound healing.
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The anti-infective mechanisms of probiotics in patients with DFU may be because of the enhance ability to fight with the pathogenic microbes or to modulate the host's immune responses and the production of various antimicrobial substances, such as organic acids, hydrogen peroxide, low molecular weight antimicrobial substances, diacetyl, bacteriocins, and their anti-inflammatory properties. 6, 31 We found that probiotic supplementation for 12 weeks in patients with diabetes who suffer from DFU significantly decreased FPG, insulin, HOMA-IR, HbA1c, and total cholesterol but did not affect HOMA-B and other lipid profiles. Our previous study demonstrated that probiotic supplementation for 6 weeks among women with gestational diabetes had beneficial effects on the glucose metabolism, triglycerides, and VLDL-cholesterol levels but did not influence other lipid concentrations. 32 Some researchers also exhibited that probiotic intake for 8 weeks among patients with type 2 DM 8 and patients with rheumatoid arthritis could significantly improve markers of insulin metabolism, whereas other studies concluded that this approach had no significant effects among overweight men and women, 33 and healthy volunteers. 34 Various studies have demonstrated controversial results, of which some reported that probiotic supplementation significantly reduced lipid MDA (μmol/L) 3.6 ± 0.7 3.4 ± 0.7 −0.2 ± 0.8 3.9 ± 0.7 3.1 ± 0.5 −0.8 ± 0.8 .001
All values are means ± SDs.
a P values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA).
b Obtained from Fisher's exact test.
Abbreviations: ESR, erythrocyte sedimentation rate; FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; HOMA-B, homeostasis model of assessment-estimated B cell function; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check index; TAC, total antioxidant capacity.
profiles, 10, 35 while some studies did not report any improvements in lipid profiles. 36, 37 Hyperglycaemia and hyperinsulinemia are associated with an acceleration of arteriosclerotic and atherosclerotic changes of the greater arteries resulting in the decreased blood flow, further contributing to a limb-threatening ischemic condition. 38 Therefore, improvement in glucose metabolism has been suggested as an effective means to delay vascular complications in DFU subjects. Improved glucose metabolism by increased intake of probiotics in patients with diabetes who suffer from DFU could be due to suppressing the nuclear factor-kappaB pathway 39 and gut microbiota-short-chain fatty acid (SCFA)-hormone axis. 40 Probiotics can lower the blood cholesterol by producing SCFA via the blockage of the synthesis of hepatic cholesterol and/or redirecting plasma cholesterol toward the liver and producing bile acids through deconjugating the bile salts in the small intestine. 41, 42 It must be kept in mind that in our study, probiotic supplementation let 45 However, an 8-week probiotic supplementation did not affect CRP levels in women with polycystic ovary syndrome. 46 Songisepp et al 47 also found a significant improvement in total antioxidant status after receiving probiotics for 3 weeks in healthy subjects. In patients with DFU, "adipovascular axis" expression in lower concentrations of adiponectin and higher levels of inflammatory factors could be linked to the foot ulcer pathogenesis by the microvascular and inflammatory mechanisms. 48 Therefore, to manage and control parameters of the inflammation and oxidative stress are important factors in the cutaneous wound healing process. Probiotics may help to improve inflammatory factors through producing SCFA in the gut 42 and reducing production of hydrogen peroxide radicals. 49 Furthermore, the beneficial effects of probiotics on oxidative stress might be related to the production of butyrate in the colon, 50 and its impact on decreased lipid peroxidation, such as oxidized LDL, 8-isoprostanes, and GSH redox ratio. 51 This study had few limitations. In the current study, we did not measure faecal bacteria loads before and after probiotic administration, and characterization of the microbiome at baseline, during and after therapy. Future studies are suggested to tailor probiotic therapy to the individual patient. Another limitation was that we could not assess a direct dynamic test such as glucose tolerance test or hyperinsulinemic clamp in the current study. Therefore, this should be taken into account in the interpretation of our findings. We also did not take bacterial cultures. Further studies are needed to clarify the mechanisms and address the time for healing, including probiotic effects on the stromal cell-derived factor-1 and circulating endothelial progenitor cells.
Overall, probiotic supplementation for 12 weeks among subjects with DFU had beneficial effects on ulcer size, glycaemic control, total cholesterol, hs-CRP, plasma NO, TAC, and MDA levels but did not affect HOMA-B, other lipid profiles, and biomarkers of inflammation and oxidative stress.
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